Copyright Reports & Markets. All rights reserved.

Global Opioid-Induced Constipation Market Growth 2019-2024

Request for Sample of this report
Buy now

Table of Contents

    2019-2024 Global Opioid-Induced Constipation Consumption Market Report

      1 Scope of the Report

      • 1.1 Market Introduction
      • 1.2 Research Objectives
      • 1.3 Years Considered
      • 1.4 Market Research Methodology
      • 1.5 Economic Indicators
      • 1.6 Currency Considered

      2 Executive Summary

      • 2.1 World Market Overview
        • 2.1.1 Global Opioid-Induced Constipation Consumption 2014-2024
        • 2.1.2 Opioid-Induced Constipation Consumption CAGR by Region
      • 2.2 Opioid-Induced Constipation Segment by Type
        • 2.2.1 Methylnaltrexone Bromide
        • 2.2.2 Lubiprostone
        • 2.2.3 Naloxegol
        • 2.2.4 Others
      • 2.3 Opioid-Induced Constipation Consumption by Type
        • 2.3.1 Global Opioid-Induced Constipation Consumption Market Share by Type (2014-2019)
        • 2.3.2 Global Opioid-Induced Constipation Revenue and Market Share by Type (2014-2019)
        • 2.3.3 Global Opioid-Induced Constipation Sale Price by Type (2014-2019)
      • 2.4 Opioid-Induced Constipation Segment by Application
        • 2.4.1 Hospital
        • 2.4.2 Pharmacy
      • 2.5 Opioid-Induced Constipation Consumption by Application
        • 2.5.1 Global Opioid-Induced Constipation Consumption Market Share by Application (2014-2019)
        • 2.5.2 Global Opioid-Induced Constipation Value and Market Share by Application (2014-2019)
        • 2.5.3 Global Opioid-Induced Constipation Sale Price by Application (2014-2019)

      3 Global Opioid-Induced Constipation by Players

      • 3.1 Global Opioid-Induced Constipation Sales Market Share by Players
        • 3.1.1 Global Opioid-Induced Constipation Sales by Players (2017-2019)
        • 3.1.2 Global Opioid-Induced Constipation Sales Market Share by Players (2017-2019)
      • 3.2 Global Opioid-Induced Constipation Revenue Market Share by Players
        • 3.2.1 Global Opioid-Induced Constipation Revenue by Players (2017-2019)
        • 3.2.2 Global Opioid-Induced Constipation Revenue Market Share by Players (2017-2019)
      • 3.3 Global Opioid-Induced Constipation Sale Price by Players
      • 3.4 Global Opioid-Induced Constipation Manufacturing Base Distribution, Sales Area, Product Types by Players
        • 3.4.1 Global Opioid-Induced Constipation Manufacturing Base Distribution and Sales Area by Players
        • 3.4.2 Players Opioid-Induced Constipation Products Offered
      • 3.5 Market Concentration Rate Analysis
        • 3.5.1 Competition Landscape Analysis
        • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
      • 3.6 New Products and Potential Entrants
      • 3.7 Mergers & Acquisitions, Expansion

      4 Opioid-Induced Constipation by Regions

      • 4.1 Opioid-Induced Constipation by Regions
        • 4.1.1 Global Opioid-Induced Constipation Consumption by Regions
        • 4.1.2 Global Opioid-Induced Constipation Value by Regions
      • 4.2 Americas Opioid-Induced Constipation Consumption Growth
      • 4.3 APAC Opioid-Induced Constipation Consumption Growth
      • 4.4 Europe Opioid-Induced Constipation Consumption Growth
      • 4.5 Middle East & Africa Opioid-Induced Constipation Consumption Growth

      5 Americas

      • 5.1 Americas Opioid-Induced Constipation Consumption by Countries
        • 5.1.1 Americas Opioid-Induced Constipation Consumption by Countries (2014-2019)
        • 5.1.2 Americas Opioid-Induced Constipation Value by Countries (2014-2019)
      • 5.2 Americas Opioid-Induced Constipation Consumption by Type
      • 5.3 Americas Opioid-Induced Constipation Consumption by Application
      • 5.4 United States
      • 5.5 Canada
      • 5.6 Mexico
      • 5.7 Key Economic Indicators of Few Americas Countries

      6 APAC

      • 6.1 APAC Opioid-Induced Constipation Consumption by Countries
        • 6.1.1 APAC Opioid-Induced Constipation Consumption by Countries (2014-2019)
        • 6.1.2 APAC Opioid-Induced Constipation Value by Countries (2014-2019)
      • 6.2 APAC Opioid-Induced Constipation Consumption by Type
      • 6.3 APAC Opioid-Induced Constipation Consumption by Application
      • 6.4 China
      • 6.5 Japan
      • 6.6 Korea
      • 6.7 Southeast Asia
      • 6.8 India
      • 6.9 Australia
      • 6.10 Key Economic Indicators of Few APAC Countries

      7 Europe

      • 7.1 Europe Opioid-Induced Constipation by Countries
        • 7.1.1 Europe Opioid-Induced Constipation Consumption by Countries (2014-2019)
        • 7.1.2 Europe Opioid-Induced Constipation Value by Countries (2014-2019)
      • 7.2 Europe Opioid-Induced Constipation Consumption by Type
      • 7.3 Europe Opioid-Induced Constipation Consumption by Application
      • 7.4 Germany
      • 7.5 France
      • 7.6 UK
      • 7.7 Italy
      • 7.8 Russia
      • 7.9 Spain
      • 7.10 Key Economic Indicators of Few Europe Countries

      8 Middle East & Africa

      • 8.1 Middle East & Africa Opioid-Induced Constipation by Countries
        • 8.1.1 Middle East & Africa Opioid-Induced Constipation Consumption by Countries (2014-2019)
        • 8.1.2 Middle East & Africa Opioid-Induced Constipation Value by Countries (2014-2019)
      • 8.2 Middle East & Africa Opioid-Induced Constipation Consumption by Type
      • 8.3 Middle East & Africa Opioid-Induced Constipation Consumption by Application
      • 8.4 Egypt
      • 8.5 South Africa
      • 8.6 Israel
      • 8.7 Turkey
      • 8.8 GCC Countries

      9 Market Drivers, Challenges and Trends

      • 9.1 Market Drivers and Impact
        • 9.1.1 Growing Demand from Key Regions
        • 9.1.2 Growing Demand from Key Applications and Potential Industries
      • 9.2 Market Challenges and Impact
      • 9.3 Market Trends

      10 Marketing, Distributors and Customer

      • 10.1 Sales Channel
        • 10.1.1 Direct Channels
        • 10.1.2 Indirect Channels
      • 10.2 Opioid-Induced Constipation Distributors
      • 10.3 Opioid-Induced Constipation Customer

      11 Global Opioid-Induced Constipation Market Forecast

      • 11.1 Global Opioid-Induced Constipation Consumption Forecast (2019-2024)
      • 11.2 Global Opioid-Induced Constipation Forecast by Regions
        • 11.2.1 Global Opioid-Induced Constipation Forecast by Regions (2019-2024)
        • 11.2.2 Global Opioid-Induced Constipation Value Forecast by Regions (2019-2024)
        • 11.2.3 Americas Consumption Forecast
        • 11.2.4 APAC Consumption Forecast
        • 11.2.5 Europe Consumption Forecast
        • 11.2.6 Middle East & Africa Consumption Forecast
      • 11.3 Americas Forecast by Countries
        • 11.3.1 United States Market Forecast
        • 11.3.2 Canada Market Forecast
        • 11.3.3 Mexico Market Forecast
        • 11.3.4 Brazil Market Forecast
      • 11.4 APAC Forecast by Countries
        • 11.4.1 China Market Forecast
        • 11.4.2 Japan Market Forecast
        • 11.4.3 Korea Market Forecast
        • 11.4.4 Southeast Asia Market Forecast
        • 11.4.5 India Market Forecast
        • 11.4.6 Australia Market Forecast
      • 11.5 Europe Forecast by Countries
        • 11.5.1 Germany Market Forecast
        • 11.5.2 France Market Forecast
        • 11.5.3 UK Market Forecast
        • 11.5.4 Italy Market Forecast
        • 11.5.5 Russia Market Forecast
        • 11.5.6 Spain Market Forecast
      • 11.6 Middle East & Africa Forecast by Countries
        • 11.6.1 Egypt Market Forecast
        • 11.6.2 South Africa Market Forecast
        • 11.6.3 Israel Market Forecast
        • 11.6.4 Turkey Market Forecast
        • 11.6.5 GCC Countries Market Forecast
      • 11.7 Global Opioid-Induced Constipation Forecast by Type
      • 11.8 Global Opioid-Induced Constipation Forecast by Application

      12 Key Players Analysis

      • 12.1 Takeda Pharmaceuticals
        • 12.1.1 Company Details
        • 12.1.2 Opioid-Induced Constipation Product Offered
        • 12.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.1.4 Main Business Overview
        • 12.1.5 Takeda Pharmaceuticals News
      • 12.2 Bayer
        • 12.2.1 Company Details
        • 12.2.2 Opioid-Induced Constipation Product Offered
        • 12.2.3 Bayer Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.2.4 Main Business Overview
        • 12.2.5 Bayer News
      • 12.3 Sanofi
        • 12.3.1 Company Details
        • 12.3.2 Opioid-Induced Constipation Product Offered
        • 12.3.3 Sanofi Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.3.4 Main Business Overview
        • 12.3.5 Sanofi News
      • 12.4 Mallinckrodt
        • 12.4.1 Company Details
        • 12.4.2 Opioid-Induced Constipation Product Offered
        • 12.4.3 Mallinckrodt Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.4.4 Main Business Overview
        • 12.4.5 Mallinckrodt News
      • 12.5 Salix (Bausch Health)
        • 12.5.1 Company Details
        • 12.5.2 Opioid-Induced Constipation Product Offered
        • 12.5.3 Salix (Bausch Health) Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.5.4 Main Business Overview
        • 12.5.5 Salix (Bausch Health) News
      • 12.6 AstraZeneca
        • 12.6.1 Company Details
        • 12.6.2 Opioid-Induced Constipation Product Offered
        • 12.6.3 AstraZeneca Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.6.4 Main Business Overview
        • 12.6.5 AstraZeneca News
      • 12.7 Progenics Pharmaceuticals
        • 12.7.1 Company Details
        • 12.7.2 Opioid-Induced Constipation Product Offered
        • 12.7.3 Progenics Pharmaceuticals Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.7.4 Main Business Overview
        • 12.7.5 Progenics Pharmaceuticals News
      • 12.8 Purdue Pharm
        • 12.8.1 Company Details
        • 12.8.2 Opioid-Induced Constipation Product Offered
        • 12.8.3 Purdue Pharm Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.8.4 Main Business Overview
        • 12.8.5 Purdue Pharm News
      • 12.9 Nektar Therapeutics
        • 12.9.1 Company Details
        • 12.9.2 Opioid-Induced Constipation Product Offered
        • 12.9.3 Nektar Therapeutics Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.9.4 Main Business Overview
        • 12.9.5 Nektar Therapeutics News
      • 12.10 Daiichi Sankyo
        • 12.10.1 Company Details
        • 12.10.2 Opioid-Induced Constipation Product Offered
        • 12.10.3 Daiichi Sankyo Opioid-Induced Constipation Sales, Revenue, Price and Gross Margin (2017-2019)
        • 12.10.4 Main Business Overview
        • 12.10.5 Daiichi Sankyo News
      • 12.11 Prestige
      • 12.12 GSK
      • 12.13 Shionogi

      13 Research Findings and Conclusion

      Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.
      In the last several years, global market of Opioid-Induced Constipation developed smoothly, with an average growth rate of 3.85% from the forecast period 2019 to 2025.
      The classification of Opioid-Induced Constipation includes Methylnaltrexone Bromide, Lubiprostone, Naloxegol and other OTC drugs. The revenue proportion of Lubiprostone in 2017 is about 33%, and the proportion of OTC drugs is in about 34%.
      Opioid-Induced Constipation is widely sold in Hospital, Pharmacy and other field. The most proportion of Opioid-Induced Constipation is sold in Pharmacy, and the proportion in 2017 is 45.99%.

      According to this study, over the next five years the Opioid-Induced Constipation market will register a 4.4% CAGR in terms of revenue, the global market size will reach US$ 2770 million by 2024, from US$ 2240 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Opioid-Induced Constipation business, shared in Chapter 3.

      This report presents a comprehensive overview, market shares, and growth opportunities of Opioid-Induced Constipation market by product type, application, key manufacturers and key regions and countries.

      This study considers the Opioid-Induced Constipation value and volume generated from the sales of the following segments:

      Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
      Methylnaltrexone Bromide
      Lubiprostone
      Naloxegol
      Others
      Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
      Hospital
      Pharmacy

      This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
      Americas
      United States
      Canada
      Mexico
      Brazil
      APAC
      China
      Japan
      Korea
      Southeast Asia
      India
      Australia
      Europe
      Germany
      France
      UK
      Italy
      Russia
      Spain
      Middle East & Africa
      Egypt
      South Africa
      Israel
      Turkey
      GCC Countries

      The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
      Takeda Pharmaceuticals
      Bayer
      Sanofi
      Mallinckrodt
      Salix (Bausch Health)
      AstraZeneca
      Progenics Pharmaceuticals
      Purdue Pharm
      Nektar Therapeutics
      Daiichi Sankyo
      Prestige
      GSK
      Shionogi

      In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

      Research objectives
      To study and analyze the global Opioid-Induced Constipation consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
      To understand the structure of Opioid-Induced Constipation market by identifying its various subsegments.
      Focuses on the key global Opioid-Induced Constipation manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
      To analyze the Opioid-Induced Constipation with respect to individual growth trends, future prospects, and their contribution to the total market.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      To project the consumption of Opioid-Induced Constipation submarkets, with respect to key regions (along with their respective key countries).
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
      To strategically profile the key players and comprehensively analyze their growth strategies.

      Buy now